Who are Bosentan group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tracleer®, "Nefecon®","Ambrisentan", Bosentan and Sildenafil, Duo-Therapy with Sildenafil + Bosentan, SCH-58235, FDC macitentan/tadalafil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bosentan-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Bosentan group — Competitive Intelligence Brief

Bosentan group (Bosentan group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 2 Endothelin receptor antagonist Endothelin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Bosentan group (Bosentan group) — Elpen Pharmaceutical Co. Inc.. Bosentan is an endothelin receptor antagonist that works by blocking the action of endothelin-1, a potent vasoconstrictor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bosentan group TARGET	Bosentan group	Elpen Pharmaceutical Co. Inc.	phase 2	Endothelin receptor antagonist	Endothelin receptor
Tracleer®	Tracleer®	Actelion	marketed	Endothelin receptor antagonist	Endothelin receptor A (ETA) and Endothelin receptor B (ETB)
"Nefecon®","Ambrisentan"	"Nefecon®","Ambrisentan"	The First Hospital of Jilin University	marketed	Endothelin receptor antagonist (ERA)	Endothelin receptor type A (ETA)
Bosentan and Sildenafil	Bosentan and Sildenafil	Rigshospitalet, Denmark	phase 3	Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination	Endothelin receptors (ETA/ETB) and phosphodiesterase-5
Duo-Therapy with Sildenafil + Bosentan	Duo-Therapy with Sildenafil + Bosentan	Johns Hopkins University	phase 3	Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist	PDE-5; Endothelin receptor A and B
SCH-58235	SCH-58235	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
FDC macitentan/tadalafil	FDC macitentan/tadalafil	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist class)

AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Actelion · 2 drugs in this class
Bayer · 1 drug in this class
Dr Sudarshan Rajagopal · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Elpen Pharmaceutical Co. Inc. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bosentan group — Competitive Intelligence Brief. https://druglandscape.com/ci/bosentan-group. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab